With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies.
The investment arms of Bayer, Hitachi, Samsung, Sony Innovation Fund by IGV, Unilever and the PE fund HAT are financing Huma Therapeutics Ltd to the tune of approximately $130 million.
Longevity.Technology: This sizeable investment will scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research and expand their presence globally after last year’s acquisition of AI and wearables companies Biobeat and Tarilian Laser Technologies.
As interventions lead to longer lifespans and an aging population, aging in place continues to gather investment and inform strategy at a government level; Longevity.Technology is preparing a market intelligence report on the sector, and this is available to pre-order.
Leaps by Bayer and Hitachi Ventures led the Huma Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
A further commitment of $70 million that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than $200 million. Goldman Sachs International acted as lead placement agent to Huma. HSBC Bank plc and Nomura acted as joint placement agents, with the latter also becoming a shareholder.
“This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives.”
The new investment will be used to expand Huma’s digital platform in the US, Asia and the Middle East, with Huma having recently been named Europe’s fastest growing healthcare company by the Financial Times. Huma has an established health technology and innovation partnership with four national governments (England’s NHS, Wales, Germany and UAE). Its digital ‘hospital at home’ was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90%. The service is supporting governments’ pandemic responses on a not-for-profit basis and is now used for a range of patients including those going through knee- and hip-replacement surgery, for example with Smith+Nephew.
Huma advanced its work in the US in 2021, fostering new partnerships with clinical research organisations, health care providers, payers, research organisations and tech companies.
Dan Vahdat, Founder and CEO of Huma, said: “This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives. We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide .’’
Alan Milburn, former UK Health Secretary and Chairman of Huma’s Board, said: “This is a significant moment in Huma’s history and I will work to build enduring, trusted relationships with our new partners. We are living through unprecedented times and the importance of health and well-being is underlined as never before. Together with our partners we can use our expertise, technology, and innovation to change the face of healthcare and research and impact people’s health everywhere .”
Huma’s ambition to improve people’s health across the world will be accelerated with its new global partnerships. Juergen Eckhardt, Head of Leaps by Bayer, commented: “Aligned with the vision of Leaps by Bayer, Huma’s expertise and technology will help drive a global paradigm shift towards prevention and care and may boost research efforts using data and digital technology. We invest into the most disruptive technologies of our time that have the potential to change the world for the better. As an early investor into Huma we know how perfectly the company fits into that frame as one of the leading digital innovators in healthcare and lifesciences .”